Filing Details
- Accession Number:
- 0000899243-21-032753
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-12 16:20:48
- Reporting Period:
- 2021-08-10
- Accepted Time:
- 2021-08-12 16:20:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1680581 | Fulcrum Therapeutics Inc. | FULC | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1619846 | Bryan Stuart | C/O Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge MA 02139 | See Remarks | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-08-10 | 32,000 | $7.84 | 32,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-08-10 | 32,000 | $17.50 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-08-11 | 28,000 | $7.84 | 28,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-08-11 | 28,000 | $23.75 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2021-08-10 | 32,000 | $0.00 | 32,000 | $7.84 |
Common Stock | Stock Option (right to buy) | Disposition | 2021-08-11 | 28,000 | $0.00 | 28,000 | $7.84 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
271,571 | 2028-12-17 | No | 4 | M | Direct | |
243,571 | 2028-12-17 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.
- This option was granted on December 18, 2018 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of December 18, 2018. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.